Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.77 |
| ▸ | YAP1 | P46937 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27218080 | 0.99 | ALOX15 (0.74) | ALOX15YAP1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL5836935 | 0.96 | ALOX15 (0.70) | ALOX15YAP1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL23971034 | 0.93 | ALOX15 (0.66) | ALOX15YAP1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL21310999 | 0.88 | ALOX15 (0.60) | ALOX15YAP1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL7188680 | 0.88 | ALOX15 (0.60) | ALOX15YAP1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL7188685 | 0.88 | ALOX15 (0.60) | ALOX15YAP1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2032512 | 0.87 | ALOX15 (1.00) | ALOX15YAP1NPC1RAB9AMAPT | |
| SCHEMBL15321351 | 0.87 | ALOX15 (1.00) | ALOX15YAP1NPC1RAB9AMAPT | |
| SCHEMBL15319744 | 0.87 | ALOX15 (1.00) | ALOX15YAP1NPC1RAB9AMAPT | |
| SCHEMBL15320214 | 0.87 | ALOX15 (1.00) | ALOX15YAP1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192849-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192849-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210299107-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-09-30 | — | — | US | disclosed |
| EP-3791870-A1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3791870-A1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | The Trustees of Columbia University in the City of New York (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3384908-B1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | UNIV COLUMBIA (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3384908-B1 | MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | UNIV COLUMBIA (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10597381-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597381-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190292135-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-09-26 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1631554-A2 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-07-14 | — | — | US | disclosed |
| WO-2004108687-A2 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1429759-A4 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6803374-B2 | INHIBIT THE RNA-DEPENDENT RNA POLYMERASE (RDRP) ENCODED BY HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| EP-1429759-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040067976-A1 | Compounds useful for treating Hepatitis C virus | PRIESTLEY ELDON SCOTT (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-17 | — | — | US | disclosed |
| WO-2003026587-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067976-A1 | Compounds useful for treating Hepatitis C virus | OAT, HAVCR2, GOT1 | ALOX15 1680/4885YAP1 4248/4885KDM4E 4008/4885 |
| US-10597381-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | AIFM2, GPX1, GPX4 | ALOX15 93/4885YAP1 2396/4885KDM4E 3002/4885 |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | EIF2AK2, MAVS, NSUN3 | ALOX15 3147/4885YAP1 4569/4885KDM4E 2235/4885 |
| US-20190292135-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, GPX4 | ALOX15 92/4885YAP1 2580/4885KDM4E 3174/4885 |
| US-20210299107-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, SLC7A11 | ALOX15 286/4885YAP1 2604/4885KDM4E 3253/4885 |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | OAT, HAVCR2, GOT1 | ALOX15 1680/4885YAP1 4248/4885KDM4E 4008/4885 |
| US-11192849-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | AIFM2, GPX1, GPX4 | ALOX15 92/4885YAP1 2580/4885KDM4E 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.